<DOC>
	<DOCNO>NCT01613716</DOCNO>
	<brief_summary>This study examine use dexamethasone implant ( Ozurdex ) patient macular edema associate epiretinal preretinal membrane require surgical intervention . After surgery perform ( par plana vitrectomy ) , Ozurdex implant place eye . Patients follow 1 year .</brief_summary>
	<brief_title>Ozurdex Diabetic Macular Edema Treated With Pars Plana vitrEctomy Membrane RemovAl ( OPERA Study )</brief_title>
	<detailed_description>The purpose study examine use Ozurdex patient undergoing par plana vitrectomy macular edema due preretinal membrane . Specifically , examine effect macular edema ( measure OCT ) , visual recovery ( measure visual acuity ) . We examine use patient underwent par plana vitrectomy macular edema associate taut membrane . This prospective pilot study patient receive Ozurdex implant time vitrectomy .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Epiretinal Membrane</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Patients undergoing par plana vitrectomy : Epiretinal membrane/vitreomacular traction Diabetic macular edema 2 . Patients macular edema measure OCT ( least 250 um central subfoveal thickness ) 3 . Informed consent requirement : All study subject must agree participate study provide write informed consent , write English . 4 . Age 1885 year old 1 . Age &lt; 18 year &gt; 85 year 2 . History macular edema due diseases inclusion criterion study eye History active inflammatory eye disease ( uveitis ) ( within 3 month ) History ocular malignancy and/or ocular/orbital irradiation History recent retinal vein occlusion ( within 6 month ) History neovascular agerelated macular degeneration choroidal neovascular membrane [ History juxtafoveal telangiectasia History Coat 's disease History central serous choroidoretinopathy History previous infectious retinitis ( toxoplasmosis , acute retinal necrosis , tuberculosis , etc ) 3 . Patients history intraocular infection study eye ( i.e . viral retinitis , endophthalmitis ) 4 . Patients cognitively impaired unable provide inform write consent 5 . Patients history glaucoma study eye ( define increase cup disc ratio associate nerve damage . Patients ocular hypertension control topical glaucoma drop ( maximum 3 ) exclude ) . 6 . Patient recent intravitreal injection steroid antiVEGF medication study eye ( within past 4 week ) . 7 . Patients recent periocular steroid injection ( within past 4 week ) study eye 8 . Patients topical NSAIDS drop ( patient eligible discontinue use topical NSAIDs time study enrollment ) study eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Macular Edema</keyword>
	<keyword>Epiretinal Membrane</keyword>
	<keyword>Vitrectomy</keyword>
</DOC>